Efficacy and pharmacokinetics of ozoralizumab, an anti-TNFα NANOBODY® compound, in patients with rheumatoid arthritis: 52-week results from the OHZORA and NATSUZORA trials.

Autor: Takeuchi, Tsutomu, Chino, Yukihiro, Kawanishi, Masafumi, Nakanishi, Megumi, Watase, Hirotaka, Mano, Yoko, Sato, Yuri, Uchida, Saeko, Tanaka, Yoshiya
Zdroj: Arthritis Research & Therapy; 4/13/2023, Vol. 25 Issue 1, p1-13, 13p
Databáze: Complementary Index
Externí odkaz: